Oric Pharmaceuticals (ORIC) investor relations material

Executive summary

• Advanced two lead clinical programs, rinzimetostat and enozertinib, following a strategic pipeline prioritization and a 20% workforce reduction in Q4 2025.

• Initiated Himalayas-1, a global Phase 3 trial for rinzimetostat in mCRPC patients previously treated with abiraterone, enrolling approximately 600 patients across 25 countries, with Bayer providing darolutamide supply at no cost.

• Entered clinical trial collaborations with Bayer and Johnson & Johnson, retaining full global rights to rinzimetostat.

• Enozertinib continues in Phase 1b trials for NSCLC, with data and potential registrational trial initiation expected in the second half of 2026.

• No products approved or revenue generated; operations funded by equity offerings and private placements.

Financial highlights

• Net loss for the six months ended June 30, 2026, was $77.3 million, up from $66.4 million year-over-year.

• Cash, cash equivalents, and investments totaled $387.6 million at quarter-end, expected to fund operations into the second half of 2028.

• R&D expenses rose to $67.7 million for the six months, with Q2 2026 R&D expenses at $36.3 million, mainly due to increased external costs for rinzimetostat.

• General and administrative expenses were $17.2 million for the six months, with Q2 2026 G&A expenses at $9.0 million, up slightly year-over-year.

• Accumulated deficit reached $769.5 million as of June 30, 2026.

Outlook and guidance

• Cash and investments projected to fund operations into the second half of 2028, beyond the anticipated primary endpoint readout for the first Phase 3 rinzimetostat trial.

• Key program updates for rinzimetostat and enozertinib, including clinical data presentations and potential registrational trial initiation, expected in 2H 2026.

• Plans to seek additional capital as needed through equity, debt, or strategic partnerships.